Growth hormone release by the novel GH releasing peptide hexarelin in patients with homozygous β-thalassemia

Journal of Pediatric Endocrinology and Metabolism

Volumn 10, Issue 1, 1997, Pages 35-40

  Tolis, G ^a,f   Karydis, I ^a,b   Markousis, V ^b   Karagiorga, M ^d   Mesimeris, T ^c   Lenaerts, V ^e   Deghenghi, R ^e  

^a UNIVERSITY OF ATHENS   (Greece)

^b KAT HOSPITAL   (Greece)

^c Aghios Pavlos Gen Hosp T   (Greece)

^d AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

^e Ardana   (France)

^f IASO GENERAL HOSPITAL   (Greece)

Author keywords

thalassemia; GH release; GH secretagogues; growth; Hexarelin; short stature

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; HEXARELIN;

ADOLESCENT; ADULT; ARTICLE; BETA THALASSEMIA; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; GROWTH HORMONE RELEASE; GROWTH REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; SCHOOL CHILD; SCORING SYSTEM; SHORT STATURE; THALASSEMIA MAJOR;

ADOLESCENT; ADULT; AMINO ACID SEQUENCE; BETA-THALASSEMIA; CHILD; FEMALE; GROWTH SUBSTANCES; HUMAN GROWTH HORMONE; HUMANS; KINETICS; MALE; OLIGOPEPTIDES; SERMORELIN;

EID: 0030993140     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Vullo C, de Sanctis V, Katz M, Wonke B, Hoffbrand AV, Bagni B, Torresani T, Tolis G, Maseiro M, Di Palma A, Borgatti L. Endocrine abnormalities in thalassemia. Ann NY Acad Sci 1990; 612: 293-298.
2. Scacchi M, Danesi L, De Martin M, Dubini A, Forni L, Masala A, Gallisai D, Burrai C, Terzoli S, Boffa C, Marzano C, Cavagnini F. Treatment with biosynthetic growth hormone of short thalassemic patients with impaired growth hormone secretion. Clin Endocrinol 1991; 35: 335-339.
3. Momany FA, Bowers CY, Reynolds GA, Chang D, Hong A, Newlander K. Design, synthesis and biological activity of peptides which release growth hormone in vitro. Endocrinology 1981; 121: 1531-1536.
4. Codd EE, Yellin T, Walker RF. Binding of GHRH and enkephalin-derived GHRPs to mu and delta opioid receptors in forebrain of rat. Neuropharmacology 1988; 27: 1019-1025.
5. Bowers CY. GH releasing peptides - structure and kinetics. J Pediatr Endocrinol 1993; 6: 21-31.
6. Deghenghi R, Cananzi M, Battisti C, Locatelli V, Muller EE. Hexarelin (EP 23905): a superactive growth hormone releasing peptide. J Endocrinol Invest 1992; 25 (Suppl 4): 45.
7. Smith RG, Cheng K, Schoen WR, Pong SS, Hickey G, Jacks T, Butler B, Chan WWS, Chaung LYP, Judith F, Taylor J, Wyvratt MJ, Fisher MH. A non-peptidyl growth hormone secretagogue. Science 1993; 260: 1640-1643.
8. Ilson BE, Jorkarsky DK, Cumow RT, Stole RM. Effect of a new synthetic hexapeptide to selectively stimulate growth hormone release in healthy human subjects. J Clin Endocrinol Metab 1989; 69; 212-214.
9. Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thomer MO. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab 1990; 70: 975-982.
10. Hartman ML, Farello G, Pezzoli S, Thorner MO. Oral administration of growth hormone (GH)-releasing peptide stimulates GH secretion in normal men. J Clin Endocrinol Metab 1992; 74: 1378-1384.
11. Bowers CY, Alster DK, Frentz JM. The growth hormone-releasing activity of a synthetic peptide in normal men and short statured children after oral administration. J Clin Endocrinol Metab 1992; 74: 292-298.
12. Tolis G, Mesimeris R, Deghenghi R, Boutignon F. Wuthrich P, Lenaerts V. Growth hormone release in thalassemic patients by a new GH-releasing peptide administered intravenously or orally. 75th Annual Meeting, The Endocrine Society, Las Vegas, USA, June 1993;Abstr331, p 133.
13. Reynolds GA, Bowers CY, Granda-Ayala P, Garcia M. Dimensions of GH releasing peptides (GHRPs). 75th Annual Meeting, The Endocrine Society, Las Vegas, USA, June 1993; Abstr 1450, p 413.
14. Ghigo E, Arvat E, Gianotti L, Imbibo BP, Lenaerts V, Deghenghi R, Camanni F. Growth hormone-releasing activity of Hexarelin, a new synthetic peptide, after intravenous, subcutaneous, intranasal and oral administration in man. J Clin Endocrinol Metab 1994; 78: 693-698.
15. Laron Z, Frenkel J, Gil-Ad I, Klinger B, Lubin E, Wuthrich P, Boutignon F, Lenaerts V, Deghenghi R. Growth hormone releasing activity by intranasal administration of a synthetic hexapeptide (hexarelin). Clin Endocrinol 1994; 41: 539-541.
16. Mericq V, Cassorla F, Garcia H, Avila A, Bowers C, Merriam G. Growth hormone responses to GH-releasing peptide and to GH-releasing hormone in GH-deficient children. J Clin Endocrinol Metab 1995; 80: 1681-1684.
17. Psilonis M, Larmou C, Costeas A, Tolis G. Anterior pituitary function and growth hormone secretion in beta homozygous thalassemia. 70th Annual Meeting, The Endocrine Society, New Orleans, USA, June 1988; Abst 389, p 118.
18. Torsello A, Locatelli V, Deghenghi R, Tolis G, Vrontakis ME. Galanin immunoneutralization inhibits Hexarelin stimulation of GH secretion in the rat. 77th Annual Meeting, The Endocrine Society, Washington, USA, June 1995; Abstr P3-110, p 496.
19. Scacchi M, Pincelli AI, Danesi L, Cavagnini F. Growth hormone releasing activity of hexarelin in anorexia nervosa. 10th International Congress of Endocrinology, San Francisco, USA, June 1996; Abstr P3-66, p 771.
20. De Marinis L, Mancini A, Valle D, Bianchi A, Gentilella R, Zaltieri G, Giustina A. GH response to hexarelin after meal in normal subjects: preliminary data. 10th International Congress of Endocrinology, San Francisco, USA, June 1996; Abstr P2-459, p 519.
21. Clark RG, Carlsson L, Trojnar J, Robinson ICAF. The effect of growth hormone-releasing peptide and growth hormone-releasing factor on conscious and anaesthetized rats. J Neuroendocrinol 1989; 1: 249-255.
22. Hickey JG, Baumhover J, Faidley T, et al. Effect of hypothalamo-pituitary stalk transection in the pig on GH secretory activity of L-692585. 76th Annual Meeting, The Endocrine Society, Anaheim, CA, USA, June 1994; Abstr 661, p 366.
23. Smith RG. Modulation of pulsatile GH release by an orally active GH secretagogue. 10th International Congress of Endocrinology, San Francisco, USA, June 1996; Abstr S-10-1, p 26.
24. Hindmarsh PC, Brook CGD. Disorders of stature. In: Grossman A, ed, Clinical Endocrinology. Oxford: Blackwell Scientific, 1992; 810-836.
25. Jaffe CA, Hao PJ, Demott-Friberg R, Bowers CY, Barkan AL. Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men. J Clin Endocrinol Metab 1993; 77: 1641-1667.
26. Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic heptapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology 1984; 114: 1537-1545.
27. Thorner MO, Reshke J, Chitwood J. Acceleration of growth in two children treated with human growth hormone-releasing factor. N Engl J Med 1985; 312:4-9.
28. Bach MA, Chapman I, Farmer M, Schilling L, Van Gauter E, Taylor AM, Bolognese J, Krupa D, Gormley G, Thorner MO. An orally active GH secretagogue increases pulsatile GH secretion and circulating IGF-I in the healthy elderly. 10th International Congress of Endocrinology, San Francisco, USA, June 1996; Abstr OR 15-2, p 71.